WIRB-Copernicus Group, Mytrus to deliver electronic informed consent solution

Wednesday, May 22, 2013 09:16 AM

The WIRB-Copernicus Group, the world's largest provider of regulatory and ethical review services for human research, has partnered with Mytrus, a clinical technology and services company, to deliver a unique electronic informed consent solution that will help to streamline and enrich the clinical research process.

The WIRB-Copernicus Group will be Mytrus' exclusive independent Institutional Review Boards (IRB) partner, providing Mytrus' interactive e-consent as part of its comprehensive ethical oversight solution.

"The WIRB-Copernicus Group's partnership with Mytrus is in perfect alignment with our core values and vision for the industry," said Donald A. Deieso, Ph.D., executive chairman of the WIRB-Copernicus Group. "Mytrus' technology solution brings unmatched insight and integrity to the consent process, ensuring that patients are properly informed and enabling sponsors to attain meaningful data regarding patient consent and trial enrollment. We are proud to support Mytrus in its mission to Reinvent Consent, and we are delighted to add the Mytrus e-consent application to our growing suite of ethical review solutions."

Accessible via iPad, the Mytrus internet-based application digitizes and deepens the traditionally paper-based process of obtaining patient consent for participation in clinical trials, increasing efficiency and reducing study start-up time for contract research organizations and trial sponsors. The Mytrus tool uses video, voice instruction and quizzes to maximize patient interaction, which leads to improved comprehension and retention, enabling patients to make more informed decisions regarding their participation and care. The Mytrus e-consent solution has been translated into many languages, and has been proven most successful in the management of clinical trials involving a diverse subject population. In addition to providing a rich user experience for patients, the Mytrus solution generates advanced metrics and aggregate data to optimize the practice of clinical trial management for sponsors and CRO's.

"The WIRB-Copernicus Group is recognized as a global leader, and clinical research companies look to them to provide cutting-edge solutions that dramatically impact the cost and efficiency of clinical trials," said Anthony Costello, CEO of Mytrus. "We are pleased that the WIRB-Copernicus Group has recognized the innovation of our technology and has chosen to offer our e-consent application in its comprehensive suite of research oversight solutions."

The WIRB-Copernicus Group includes Western Institutional Review Board (WIRB), Copernicus Group IRB and IRBNet, a research compliance software solution serving institutions. The WIRB-Copernicus Group is the only ethical solutions provider capable of meeting the unique needs of institutions while supporting the speed and efficiency required by industry sponsors and CROs. With a comprehensive, streamlined review service that now includes Mytrus' e-consent, and a network of clients numbering in the thousands, the WIRB-Copernicus Group connects the world's leading sponsors and CROs with experienced research institutions to deliver new therapies and treatments to market with the highest degree of efficiency, quality and integrity.

Share:          
CLINICAL TRIAL RESOURCES

Search:

NEWS ONLINE ARCHIVE

Browse by:

CWWeekly

September 30

Novartis-Walgreens pilot study blurring the line between retail pharmacy, investigative site

CISCRP to launch traveling science museum exhibit to demystify clinical trial participation

Already a subscriber?
Log in to your digital subscription.

Subscribe to CWWeekly.

The CenterWatch Monthly

October

New growth and decline in Asia clinical trials
South Korea, Japan, China see big growth in 1572s, while India posts huge drop

Harnessing Big Data to transform clinical trials
From protocol to patient recruiting, data analytics can yield valuable insights

Already a subscriber?
Log in to your digital subscription.

Purchase the October issue.

Subscribe to
The CenterWatch Monthly.

The CenterWatch Monthly

September

Sponsors look to collaborate on comparator drugs
Co-therapies, comparators are in 60% of studies, cost $25m per company a year

Early adopters implement risk-based monitoring pilot programs
Experiments aim to offer long-term solutions, despite short-term uncertainties

Already a subscriber?
Log in to your digital subscription.

Purchase the September issue.

Subscribe to
The CenterWatch Monthly.

JobWatch centerwatch.com/jobwatch

Featured Jobs